US FDA Serves One Antacid/Analgesic Question For AdComm, Opens Tap On Hangover Discussion
Executive Summary
Presentations at the US nonprescription drugs/drug safety joint advisory committee meeting will come from Bayer, marketer of the OTC brand synonymous with antacid/aspirin formulations, Alka-Seltzer, and from a firm that markets Blowfish, a caffeine/aspirin OTC indicated as a hangover remedy.
You may also be interested in...
What’s Next For Antacid/Analgesic OTCs After Negative US FDA Panel?
Nonprescription Drug and the Drug Safety and Risk Management advisory committees jointly vote 15-5 that combining antacid with aspirin, acetaminophen or other analgesic ingredients is not a combination that should be allowed under an OTC monograph.
What’s Next For Antacid/Analgesic OTCs After Negative US FDA Panel?
Nonprescription Drug and the Drug Safety and Risk Management advisory committees jointly vote 15-5 that combining antacid with aspirin, acetaminophen or other analgesic ingredients is not a combination that should be allowed under an OTC monograph.
Alka-Seltzer Antacid Will 'Plop, Plop Fizz, Fizz' Without Aspirin
In advance of a US FDA advisory panel meeting on the safety of OTC monograph antacid/aspirin products, Bayer is removing aspirin from its pioneering Alka-Seltzer effervescent indigestion products. Bayer's Andre Schmidt talks about the safety advantages and consumer trends that helped spur the change.